Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy

D. B. Calvo; Y. Z. Patt; S. Wallace; V. P. Chuang; R. S. Benjamin; J. D. Pritchard; E. M. Hersh; G. P. Bodey; G. M. Mavligit

doi:10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I

Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy

D. B. Calvo, Y. Z. Patt, S. Wallace, V. P. Chuang, R. S. Benjamin, J. D. Pritchard, E. M. Hersh, G. P. Bodey, G. M. Mavligit

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

Forty‐nine patients with regionally confined recurrent malignancy were treated with intra‐arterial cisdiamminedichloro platinum II in a Phase I‐II trial. A safe starting dose of 120 mg/m² was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra‐arterial cis‐platinum are discussed.

Original language	English (US)
Pages (from-to)	1278-1283
Number of pages	6
Journal	Cancer
Volume	45
Issue number	6
DOIs	https://doi.org/10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I
State	Published - Mar 15 1980
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I

Cite this

Calvo, D. B., Patt, Y. Z., Wallace, S., Chuang, V. P., Benjamin, R. S., Pritchard, J. D., Hersh, E. M., Bodey, G. P., & Mavligit, G. M. (1980). Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy. Cancer, 45(6), 1278-1283. https://doi.org/10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I

@article{9916119e48c94552afb78f197145468f,

title = "Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy",

abstract = "Forty‐nine patients with regionally confined recurrent malignancy were treated with intra‐arterial cisdiamminedichloro platinum II in a Phase I‐II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra‐arterial cis‐platinum are discussed.",

author = "Calvo, {D. B.} and Patt, {Y. Z.} and S. Wallace and Chuang, {V. P.} and Benjamin, {R. S.} and Pritchard, {J. D.} and Hersh, {E. M.} and Bodey, {G. P.} and Mavligit, {G. M.}",

year = "1980",

month = mar,

day = "15",

doi = "10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I",

language = "English (US)",

volume = "45",

pages = "1278--1283",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy

AU - Calvo, D. B.

AU - Patt, Y. Z.

AU - Wallace, S.

AU - Chuang, V. P.

AU - Benjamin, R. S.

AU - Pritchard, J. D.

AU - Hersh, E. M.

AU - Bodey, G. P.

AU - Mavligit, G. M.

PY - 1980/3/15

Y1 - 1980/3/15

N2 - Forty‐nine patients with regionally confined recurrent malignancy were treated with intra‐arterial cisdiamminedichloro platinum II in a Phase I‐II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra‐arterial cis‐platinum are discussed.

AB - Forty‐nine patients with regionally confined recurrent malignancy were treated with intra‐arterial cisdiamminedichloro platinum II in a Phase I‐II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra‐arterial cis‐platinum are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0018905095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018905095&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I

DO - 10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I

M3 - Article

C2 - 7188880

AN - SCOPUS:0018905095

SN - 0008-543X

VL - 45

SP - 1278

EP - 1283

JO - Cancer

JF - Cancer

IS - 6

ER -

Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this